cho-h01
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2018 (NCT03221348)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297726 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05950165 | Phase 1/Phase 2 (Phase 2) | Jan 15, 2020 | Cho Pharma Inc. |
| NCT03221348 | Phase 1 | Mar 31, 2018 | Cho Pharma Inc., Sponsor GmbH |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cho Pharma Inc. | For profit | 2 | 2 | 2 | 2018 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1